Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neckThomas Kuhnt, Juergen Dunst, Alexandra Sandner et al.|Annals of Oncology|2010Cited by 24
Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neckThomas Kuhnt, Jürgen Dunst, Peter Hass et al.|Strahlentherapie und Onkologie|2017Cited by 8
Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trialThomas Kuhnt, Juergen Dunst, Alexandra Sandner et al.|Journal of Clinical Oncology|2008Cited by 6
Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.Thomas Kuhnt, Juergen Dunst, Andreas Schreiber et al.|Journal of Clinical Oncology|2013Cited by 3
8501 ORAL Phase ll-trial of Concomitant Hyperfractionated-accelerated Radiotherapy (HART) With Cisplatin (Cis) Plus Cetuximab (Cet) for Locoregionally Advanced Inoperable Squamous Cell Head and Neck Cancer – Early Response and Acute ToxicitiesThomas Kuhnt, Juergen Dunst, Andreas Schreiber et al.|European Journal of Cancer|2011Cited by 0